Alcidion Group (ALC) investor relations material

Executive summary

• Achieved several new customer wins and expanded longstanding contracts in Q3 FY2026, advancing AI strategy and pipeline opportunities, especially in the U.K. and Australia.

• Secured first Miya Precision customer in Queensland with a five-year contract for remote patient monitoring, marking strategic entry into a new market.

• Achieved positive operating cashflow of AUD 1.7 million in Q3 FY2026, with cash receipts of AUD 14.5 million, the highest quarterly figure to date.

• Secured AUD 11.7 million in new total contract value sales, including major contract expansions and renewals in the U.K. and Australia.

• Selected as preferred provider for a significant EPR solution at University Hospitals Sussex, with contract signing expected in May 2026.

Financial highlights

• Delivered new sales with a total contract value of AUD 11.7 million across six or seven contracts, with 90% recurring product revenue.

• Contracted revenue at Q3 end was AUD 43.8 million, up 9% year-over-year, with a portion to be recognized in FY2027.

• Cash receipts from customers in Q3 were AUD 14.5 million, driving positive operating cash flow of AUD 1.7 million.

• Product development and operating costs were AUD 3.4 million, higher due to third-party partner payments and expanded contracts.

• Cash balance at March 31 was AUD 15.1 million with no debt.

Outlook and guidance

• Revenue for FY2026 expected to exceed AUD 50 million, with EBITDA above AUD 5 million.

• Q4 anticipated to be the largest cash collection quarter, supported by the expected signing of the University Hospitals Sussex contract.

• Full-year operating cash flow projected to remain positive and in line with FY2025's AUD 5.8 million.

• UHSussex contract, expected to be signed in May 2026, will materially contribute to FY2026 revenue.

• Continued optimism for new customer opportunities and geographic expansion, including Canada and the Middle East.